XOMA - XOMA Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
24.93
-0.56 (-2.20%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close25.49
Open25.78
Bid23.80 x 1200
Ask28.00 x 800
Day's Range24.74 - 26.20
52 Week Range11.02 - 26.90
Volume70,552
Avg. Volume57,643
Market Cap218.325M
Beta (3Y Monthly)1.20
PE Ratio (TTM)N/A
EPS (TTM)-0.19
Earnings DateNov 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.00
  • GlobeNewswire

    Iscalimab (CFZ533) Update

    As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candidate, for which XOMA (XOMA) has the potential to earn royalties that are tiered from a mid-single to a low teens percentage rate based on sales levels, if this investigational compound is approved and commercialized. Novartis dedicated eight (8) slides to the iscalimab update. Please find the Novartis R&D Day Presentation on the Novartis website (slide numbers 1, 2, 64-71).

  • GlobeNewswire

    XOMA Announces Commencement of Rights Offering

    Under the terms of the Rights Offering, the holders of XOMA’s common stock and Series X Preferred Stock and Series Y Preferred Stock as of 5:00 p.m., New York time, on November 29, 2019, the record date for the Rights Offering, are entitled to purchase up to 1,000,000 shares of common stock in the aggregate at a subscription price equal to $22.00 per share, or under certain circumstances, shares of non-voting Series Z preferred stock in lieu of common stock (collectively, the “Offered Shares”), as more fully described in the prospectus supplement, dated December 2, 2019, relating to the Rights Offering.

  • GlobeNewswire

    XOMA Announces Proposed Rights Offering

    Rights Offering will be available to all shareholders of record on November 29, 2019$22 million to be raised; fully backstopped EMERYVILLE, Calif., Nov. 19, 2019 -- XOMA.

  • Will XOMA Continue to Surge Higher?
    Zacks

    Will XOMA Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor XOMA.

  • GlobeNewswire

    XOMA Reports Third Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results

    EMERYVILLE, Calif., Nov. 05, 2019 -- XOMA Corporation (Nasdaq: XOMA) today reported its third quarter 2019 financial results.  “XOMA’s portfolio of future potential royalty-.

  • Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know
    Zacks

    Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know

    Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • How Much Are XOMA Corporation (NASDAQ:XOMA) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are XOMA Corporation (NASDAQ:XOMA) Insiders Spending On Buying Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • Benzinga

    The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 26.) AstraZeneca plc (NYSE: AZN ) GlaxoSmithKline ...

  • GlobeNewswire

    XOMA Acquires Royalty Interest Position in Six Clinical-Stage Assets

    XOMA Corporation (XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.  One of the assets, NIR178, is being developed by Novartis as a novel checkpoint inhibitor for the treatment of solid tumors.  Five of the assets are being developed by Palobiofarma.

  • GlobeNewswire

    XOMA to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will provide a corporate update at the 2019 Cantor Fitzgerald Global Healthcare Conference, taking place October 2-4, 2019, in New York, New York.  The presentation will take place on Wednesday, October 2, 2019 at 7:45AM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com.  An archived version of the webcast will be available for 90 days after the event. XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  For more information, visit www.xoma.com.

  • What Did XOMA Corporation's (NASDAQ:XOMA) CEO Take Home Last Year?
    Simply Wall St.

    What Did XOMA Corporation's (NASDAQ:XOMA) CEO Take Home Last Year?

    Jim Neal became the CEO of XOMA Corporation (NASDAQ:XOMA) in 2016. This report will, first, examine the CEO...

  • GlobeNewswire

    XOMA to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the H.C. Wainwright 21st Annual Global Investment Conference, in New York, New York.  The presentation will take place on Tuesday, September 10, 2019, at 10:00AM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com or by clicking http://wsw.com/webcast/hcw5/xoma/.  An archived version of the webcast will be available for 90 days after the event. EXPLANATORY NOTE: All references to “portfolio” in this press release are to milestone and/or royalty rights associated with drug products in development.  All references to “assets” in this presentation are to milestone and/or royalty rights associated with individual drug products in development.

  • Health Check: How Prudently Does XOMA (NASDAQ:XOMA) Use Debt?
    Simply Wall St.

    Health Check: How Prudently Does XOMA (NASDAQ:XOMA) Use Debt?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • GlobeNewswire

    XOMA’s Royalty Portfolio Expands Significantly

    XOMA Corporation (XOMA), today announced its portfolio of potential future royalty and milestone payments has significantly increased with the addition of Janssen Biotech, Inc. drug candidates for which XOMA could receive future milestone and royalty payments. In addition, Janssen has elected to accelerate its base annual license fee obligation and will make a one-time $2.5 million payment to XOMA. For each program, XOMA is entitled to receive milestone payments upon the achievement of certain clinical development and regulatory approval events.

  • Xoma (XOMA) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Xoma (XOMA) Reports Q2 Loss, Tops Revenue Estimates

    Xoma (XOMA) delivered earnings and revenue surprises of 14.55% and 52.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    XOMA Reports Second Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results

    Novartis’s iscalimab highlighted at key scientific conferences First patient dosed with gevokizumab in collaborator clinical study Sesen Bio announced intention to initiate.

  • A Firm's First Profit Can Mean Big Returns for Investors
    Zacks

    A Firm's First Profit Can Mean Big Returns for Investors

    A Firm's First Profit Can Mean Big Returns for Investors

  • Analysts Estimate Xoma (XOMA) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Xoma (XOMA) to Report a Decline in Earnings: What to Look Out for

    Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    XOMA to Present at the 2019 Wedbush PacGrow Healthcare Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the 2019 Wedbush PacGrow Healthcare Conference in New York, New York.  The presentation will take place on Wednesday, August 14, 2019, at 3:40PM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com or by clicking http://wsw.com/webcast/wedbush35/xoma/.  An archived version of the webcast will be available for 90 days after the event. EXPLANATORY NOTE: All references to “portfolio” in this press release are to milestone and/or royalty rights associated with drug products in development.  All references to “assets” in this presentation are to milestone and/or royalty rights associated with individual drug products in development.

  • What Kind Of Share Price Volatility Should You Expect For XOMA Corporation (NASDAQ:XOMA)?
    Simply Wall St.

    What Kind Of Share Price Volatility Should You Expect For XOMA Corporation (NASDAQ:XOMA)?

    Anyone researching XOMA Corporation (NASDAQ:XOMA) might want to consider the historical volatility of the share price...

  • GlobeNewswire

    First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma

    XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.  For more information, visit www.xoma.com.

  • If You Had Bought XOMA (NASDAQ:XOMA) Stock Five Years Ago, You'd Be Sitting On A 81% Loss, Today
    Simply Wall St.

    If You Had Bought XOMA (NASDAQ:XOMA) Stock Five Years Ago, You'd Be Sitting On A 81% Loss, Today

    XOMA Corporation (NASDAQ:XOMA) shareholders should be happy to see the share price up 17% in the last month. But will...

  • Xoma (XOMA) Surpasses Q1 Earnings and Revenue Estimates
    Zacks

    Xoma (XOMA) Surpasses Q1 Earnings and Revenue Estimates

    Xoma (XOMA) delivered earnings and revenue surprises of 261.54% and 152.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Xoma: 1Q Earnings Snapshot

    The Emeryville, California-based company said it had net income of 21 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire

    XOMA Reports First Quarter 2019 Financial Results and Operating Highlights

    Acquired rights to potential milestone and royalty payments associated with five hematology assetsReceived $5.5 million milestone paymentAdded Barbara Kosacz to XOMA’s Board of.